MC2-THERAPEUTICS
7.8.2019 15:47:12 CEST | Business Wire | Press release
MC2 Therapeutics A/S, a late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the completion of enrollment for its EU Phase 3 study assessing the safety and efficacy of MC2-01 PAD™ Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in adult patients with plaque psoriasis compared to Daivobet® gel (marketed in the US as Taclonex® Topical Suspension).
“Completion of patient enrollment in this EU Phase 3 registration study marks yet another significant and timely accomplishment for the MC2-01 PAD™ Cream global development program in plaque psoriasis following our successful US Phase 3 head-to-head study in 2018, ” stated Jesper J. Lange, CEO & President of MC2 Therapeutics. He added: “Our efforts in both EU and US demonstrate that we are committed to build leadership in topical therapies for patients with chronic inflammatory conditions. Our proprietary PAD™ Technology enables us to develop a new standard of topical therapies that combine fast and effective relief of symptoms with a unique moisturizing and cosmetic feel that we believe will significantly upgrade the patient experience and convenience in daily routines.”
About the MC2-01 PAD™ Cream Phase 3 Study
The study is a Phase 3, randomized, multicenter, investigator-blind, parallel-group study to evaluate the efficacy and safety of MC2-01 PAD™ Cream in subjects with plaque psoriasis compared to MC2-01 vehicle and Daivobet® gel. Subjects apply study medication topically once daily for up to 8 weeks. The primary objective is to show therapeutic superiority of MC2-01 PAD™ Cream to the active comparator, as well as to characterize the safety profile of MC2-01 PAD™ Cream in subjects with plaque psoriasis. The primary efficacy endpoint is percentage change from baseline in mPASI on the body at Week 8. The study enrolled 490 patients in 32 centres in Europe.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions. Using its proprietary PAD™ Technology – a unique oil-in-water dispersion – MC2 Therapeutics is developing a pipeline of novel innovative topical therapies designed for unique patient experiences.
For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190807005489/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release
Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 18:00:00 CEST | Press release
Partnership Enables Developers To Monetize Games On The Skich Store With Xsolla Handling Payments, Tax Compliance, And Commerce Infrastructure Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulat
Boomi and Guru Partner to Deliver AI-Powered Enterprise Knowledge Enriched by Real-Time Data Activation14.5.2026 16:30:00 CEST | Press release
Guru becomes a launch partner for Boomi Connect, integrating with Boomi’s managed connector service and MCP Registry to transform fragmented enterprise data into governed, actionable intelligence for AI agents Boomi, the data activation company for AI, and Guru, the AI-powered enterprise knowledge platform, today announced a technology partnership to help organizations unlock the full value of their enterprise data for AI-driven decision-making. Unveiled at Boomi World 2026, the partnership makes Guru a launch partner for Boomi Connect, Boomi’s new managed connector service, and integrates Guru’s knowledge agents with Agentstudio and the Boomi MCP Registry to deliver richer, more accurate, and more actionable insights to knowledge workers and AI agents alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514440755/en/ Guru was selected as a Boomi Connect launch partner because its AI-powered knowledge platform represents
IQM and Real Asset Acquisition Corp. Announce Public Filing of Form F-4 Registration Statement with the SEC14.5.2026 15:55:00 CEST | Press release
This filing marks an important milestone in the transaction, moving IQM closer to becoming the first European quantum computing company to go public. Global commercial leader with 23 systems sold to customers to date – including 4 out of the top 10 supercomputing centres and increasing adoption by enterprise customers. Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies1), 30+ computers built, own chip factory, assembly line and quantum data centre. The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion. With the close of this transaction, IQM’s cash position is expected to be up to EUR 397 million (USD 465 million).2 Significant business momentum, with 2025 revenue of USD 36 million3 or over EUR 31 million. IQM intends to apply for its shares to be admitted to trading on Nasdaq Helsinki following the Business Combination. IQM Finland Oy, a global leader in full-stack superconducting quantum c
MOBX to Acquire U.S. Defense Rare Earth, Critical Minerals Company14.5.2026 15:40:00 CEST | Press release
Mobix Labs (Nasdaq: MOBX) today announced a non-binding Letter of Intent to acquire Special Project Delivery LLC ("SPD"), a U.S. company building sovereign supply chains for rare earth elements, critical minerals, and energy storage. The proposed acquisition would extend Mobix Labs' national security work — already supplying U.S. and allied fighter jets, missiles, submarines, and satellites — directly into one of the world's most strategically important industrial sectors. MOBX is moving directly into the supply chain powering modern defense, aerospace, and AI infrastructure. Forward-Looking Statements This press release contains forward-looking statements regarding the proposed acquisition of Special Project Delivery LLC ("SPD"), which are subject to risks and uncertainties described in Mobix Labs' SEC filings and similar provisions under applicable non-U.S. securities laws. The Letter of Intent is non-binding, and there can be no assurance that a definitive agreement will be executed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom